Expanding Research and Development Investment
First written in FY2016. 23 of 40 entries say "Restated". Latest entry: 2026-08-07.
56 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「R&D spending on continuing operations, excluding discontinued operations, for the fiscal year was ¥109.9 billion, up 5.8% year on year, and the ratio to net sales increased 0.5 percentage points from the previous fiscal year to 10.9%.」
R&D spending on continuing operations increased to ¥109.9 billion, or 10.9% of net sales. - FY2026-H1AdvancedAnnual report
「The amount spent on R&D activities across the Group during the interim consolidated period was ¥54,635 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated period.」
R&D expenses for FY2026-H1 were ¥54,635 million, up from ¥43,206 million in the same period of the previous year, while the company stated that there had been no material changes in the status of its R&D activities. - FY2025AdvancedAnnual report
「R&D spending on continuing operations, excluding discontinued operations, for the fiscal year was ¥103.9 billion, up 21.7% year on year, and the ratio to net sales increased 1.2 percentage points from the previous fiscal year to 10.4%.」
R&D spending on continuing operations increased to ¥103.9 billion, or 10.4% of net sales. - FY2025-H1RestatedAnnual report
「The amount spent on R&D activities across the Group during the interim consolidated accounting period was ¥43,206 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company continued to invest in R&D and identified higher R&D expenses related to next-generation endoscopy systems and other projects as a factor behind the increase in selling, general and administrative expenses. - FY2024AdvancedAnnual report
「R&D spending on continuing operations, excluding discontinued operations, for the fiscal year was ¥86.4 billion, up 12.4% year on year, and the ratio to net sales increased 0.5 percentage points from the previous fiscal year to 9.2%. Taking into account the average for peer companies in the medtech industry, the company aims to invest approximately 8.5% of net sales in R&D activities in the fiscal year ending March 2026.」
R&D spending on continuing operations increased to ¥86.4 billion, or 9.2% of net sales, and the company set a target of investing approximately 8.5% in the fiscal year ending March 2026. - FY2024-Q3RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative third quarter was ¥60,965 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The company disclosed cumulative R&D expenses through FY2024-Q3 of ¥60,965 million and reconfirmed that there had been no material changes in the status of its R&D activities. - FY2024-Q2RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative second quarter was ¥35,046 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
The company disclosed cumulative R&D expenses through FY2024-Q2 of ¥35,046 million and reconfirmed that there had been no material changes in the status of its R&D activities. - FY2024-Q1RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative first quarter was ¥15,356 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
The company recorded R&D expenses of ¥15,356 million and reconfirmed that there had been no material changes in the status of its R&D activities. - FY2023AdvancedAnnual report
「R&D spending on continuing operations, excluding discontinued operations, for the fiscal year was ¥76.9 billion, up 2.2% year on year, and the ratio to net sales declined 1.3 percentage points from the previous fiscal year to 8.7%.」
R&D spending on continuing operations was ¥76.9 billion, and the company pursued greater development efficiency through concurrent engineering, project management, resource management and value engineering, among other measures. - FY2023-Q3RestatedAnnual report
「The amount spent on R&D activities for continuing operations, excluding discontinued operations, during the cumulative third quarter was ¥51,425 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The company disclosed cumulative R&D expenses for continuing operations for the third quarter of ¥51,425 million and reconfirmed that there had been no material changes in the status of its R&D activities. - FY2023-Q2RestatedAnnual report
「The amount spent on R&D activities for continuing operations, excluding discontinued operations, during the cumulative second quarter was ¥36,092 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
The company disclosed first-half R&D expenses for continuing operations of ¥36,092 million and reconfirmed that there had been no material changes in the status of its R&D activities. - FY2023-Q1RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative first quarter was ¥19,189 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
The company disclosed FY2023-Q1 R&D expenses of ¥19,189 million and reconfirmed that there had been no material changes in the status of its R&D activities. - FY2022AdvancedAnnual report
「R&D spending for the fiscal year was ¥85.3 billion, up 4.3% year on year, and the ratio to net sales declined 1.4 percentage points from the previous fiscal year to 9.8%.」
R&D spending increased from ¥81.8 billion in the previous fiscal year to ¥85.3 billion. Although the ratio to net sales declined to 9.8%, the company continued to invest in development in the medical field, AI and robotics, among others. - FY2022-Q3RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative third quarter was ¥62,529 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The company stated that there had been no material changes in its R&D policy and disclosed cumulative R&D expenses for the third quarter of ¥62,529 million. - FY2022-Q2RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative second quarter was ¥40,760 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
The company disclosed first-half R&D expenses of ¥40,760 million and reconfirmed that there had been no material changes in the status of its R&D activities. - FY2021SoftenedAnnual report
「Under this management strategy, the Group is working to innovate its R&D processes and will accelerate development by promoting front-loaded R&D and acquiring the technologies it needs through alliances and open innovation. It will also improve R&D efficiency by optimizing the costs of each R&D program while considering profitability, prioritizing programs including through project selection, and appropriately controlling spending. R&D spending on continuing operations, excluding discontinued operations, for the fiscal year was ¥81.8 billion, down 10.7% year on year, and the ratio to net sales declined 0.3 percentage points from the previous fiscal year to 11.2%.」
R&D investment declined from ¥91.6 billion in the previous fiscal year to ¥81.8 billion, and the ratio to net sales fell from 11.5% to 11.2%. The company also explicitly identified front-loading, external technology acquisition and program prioritization as efficiency measures. - FY2021-Q3RestatedAnnual report
「The amount spent on R&D activities for continuing operations, excluding discontinued operations, during the cumulative third quarter was ¥58,601 million. Although some development projects were terminated in Other businesses during the cumulative third quarter, there were no material changes in the status of other R&D activities related to continuing operations from the information disclosed in the annual securities report for the previous consolidated fiscal year.」
Cumulative R&D expenses for continuing operations for the third quarter were disclosed at ¥58,601 million. The company reconfirmed that there had been no material changes in R&D activities, other than the termination of certain development programs. - FY2021-Q2RestatedAnnual report
「The amount spent on R&D activities for continuing operations, excluding discontinued operations, during the cumulative second quarter was ¥39,017 million. Although some imaging-related development projects were terminated in Other businesses during the cumulative second quarter, there were no material changes in the status of other R&D activities related to continuing operations from the information disclosed in the annual securities report for the previous consolidated fiscal year.」
The Company disclosed first-half R&D expenses for continuing operations of ¥39,017 million and stated that, apart from the termination of some imaging-related projects, there were no material changes in its R&D activities. - FY2021-Q1RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative first quarter was ¥18,694 million. Although some development projects in the Imaging Components business were terminated during the cumulative first quarter, there were no material changes in the status of the Group's R&D activities.」
The Company disclosed first-quarter R&D expenses of ¥18,694 million and stated that, although some projects had been terminated, there were no material changes in its overall R&D activities. - FY2020SoftenedAnnual report
「R&D expenses for the consolidated fiscal year decreased 2.5% year on year to ¥91,600 million, and the ratio to net sales declined 0.3 percentage points from the previous fiscal year to 11.5%.」
R&D investment declined from ¥94,000 million in the previous fiscal year to ¥91,600 million, and the ratio to net sales fell from 11.8% to 11.5%. Meanwhile, the Company indicated a policy of improving the efficiency of and prioritizing its R&D processes. - FY2020-Q3RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative third quarter was ¥66,976 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The Company disclosed cumulative third-quarter R&D expenses of ¥66,976 million and reconfirmed that there were no material changes in the status of its R&D activities. - FY2020-Q2RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative second quarter was ¥44,819 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
The Company disclosed first-half R&D expenses of ¥44,819 million and reconfirmed that there were no material changes in the status of its R&D activities. - FY2020-Q1RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative first quarter was ¥21,195 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
The Company disclosed first-quarter R&D expenses of ¥21,195 million and stated that there were no material changes in the status of its R&D activities. - FY2019AdvancedAnnual report
「R&D expenses for the consolidated fiscal year increased 5.0% year on year to ¥94,000 million, while the ratio to net sales rose 0.4 percentage points from the previous fiscal year to 11.8%.」
R&D expenses increased to ¥94,000 million, and the ratio to net sales rose to 11.8%. - FY2019-Q3RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative third quarter was ¥68,078 million.」
The Company disclosed cumulative third-quarter R&D expenses of ¥68,078 million. - FY2019-Q1RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative first quarter was ¥21,509 million.」
The Company disclosed FY2019-Q1 R&D expenses of ¥21,509 million and stated that there were no material changes in the status of its R&D activities. - FY2018AdvancedAnnual report
「R&D expenses for the consolidated fiscal year increased 13.0% year on year to ¥89,500 million, while the ratio to net sales rose 0.7 percentage points from the previous fiscal year to 11.4%.」
R&D expenses increased to ¥89,500 million, or 11.4% of net sales. - FY2018-Q3RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative third quarter was ¥64,555 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter.」
The Company disclosed cumulative third-quarter R&D expenses of ¥64,555 million and reconfirmed that there were no material changes in the status of its R&D activities. - FY2018-Q2RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative second quarter was ¥47,140 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter.」
The Company disclosed first-half R&D expenses of ¥47,140 million and reconfirmed that there were no material changes in the policy or status of its R&D activities. - FY2018-Q1RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative first quarter was ¥23,614 million.」
The Company disclosed first-quarter R&D expenses of ¥23,614 million and stated that there were no material changes in its R&D activities. - FY2017SoftenedAnnual report
「R&D expenses for the consolidated fiscal year decreased 2.7% year on year to ¥79,200 million, while the ratio to net sales rose 0.5 percentage points from the previous fiscal year to 10.6%.」
Total R&D expenses declined 2.7% year on year to ¥79,200 million, while the ratio to net sales rose to 10.6%. - FY2017-Q3RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative third quarter was ¥54,653 million.」
The Company disclosed cumulative third-quarter R&D expenses of ¥54,653 million and stated that there were no material changes in its R&D activities. - FY2017-Q2RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative second quarter was ¥37,413 million.」
The Company disclosed first-half R&D expenses of ¥37,413 million and stated that there were no material changes in its R&D activities. - FY2017-Q1RestatedAnnual report
「The amount spent on R&D activities across the Group during the cumulative first quarter was ¥17,344 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter.」
The Company stated that there were no material changes in its R&D activities and disclosed quarterly R&D expenses of ¥17,344 million. - FY2016First statedAnnual report
「R&D expenses incurred during the consolidated fiscal year increased 9.9% year on year to ¥81,400 million, and the ratio to net sales rose 0.4 percentage points from the previous fiscal year to 10.1%.」
The Company conducts R&D in healthcare, science, imaging and company-wide common areas, with a primary focus in healthcare on early diagnosis and minimally invasive treatment.